WINNIPEG, Feb. 21, 2014 /CNW/ - Cangene Corporation ("Cangene") (TSX: CNJ) today announced that its acquisition by Emergent BioSolutions Inc. ("Emergent") (NYSE: EBS) has been completed.
Under the terms of the court-approved Plan of Arrangement, originally announced on December 11, 2013, Cangene stockholders will receive US$3.24 per share (C$3.60(1) per share) in cash, for an aggregate purchase price of US$222 million (approximately C$246 million(2) ). Payment in exchange for properly deposited shares is expected to be made within three business days.
Click here for the article.